Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929162 | 0.87 | HRH3 (0.54) | L3MBTL1LMNAMAPTKDM4EPOLB | |
| SCHEMBL2929160 | 0.87 | HRH3 (0.54) | L3MBTL1LMNAMAPTKDM4EPOLB | |
| SCHEMBL22694560 | 0.86 | KMT2A (0.51) | L3MBTL1LMNAKMT2AEPHX2 | |
| SCHEMBL241165 | 0.85 | SRD5A1 (0.62) | L3MBTL1LMNAMAPTKDM4EPOLB | |
| SCHEMBL3458256 | 0.83 | SCN1A (0.56) | LMNAKMT2AEPHX2 | |
| SCHEMBL16147114 | 0.82 | EPHX2 (0.61) | MAPTKDM4EKMT2ARAB9AEPHX2 | |
| Hydrochloric Acid SCHEMBL6444714 | 0.82 | SCN1A (0.55) | LMNAKMT2ARAB9AEPHX2 | |
| SCHEMBL4603682 | 0.81 | LMNA (0.55) | L3MBTL1LMNAMAPTKDM4EPOLB | |
| SCHEMBL20165094 | 0.81 | KMT2A (0.46) | LMNAPOLBKMT2AEPHX2 | |
| SCHEMBL20165095 | 0.81 | KMT2A (0.46) | LMNAPOLBKMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | L3MBTL1 4101/4885LMNA 2424/4885MAPT 3783/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | L3MBTL1 4168/4885LMNA 2575/4885MAPT 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.